December 6, 2017 – MONTREAL, QUEBEC – Relevium Technologies Inc. (TSX.V: “RLV” and Frankfurt: “6BX”) (the “Company” or “Relevium”) is pleased to announce the signing of an exclusive distribution agreement (the “Agreement”) with Tersus Life Sciences for Provinal® C16:1n7 a patented, ultra-purified Omega 7 fatty acid blend .
- Provinal® is a patented ultra-purified Omega 7 fatty acid blend
- Shown to decrease: insulin resistance, hepatic fat accumulation and acute and chronic inflammation – with no known side effects
- Omega global market is estimated at USD 57B by 2025 
- North American exclusivity for online sales through Amazon, Walmart/Jet and others
- Initial 2-year term
Aurelio Useche, CEO of Relevium Technologies stated: “Omega fatty acid products sell extremely well online, especially through Amazon.com.” Mr. Useche continued, “Relevium is extremely proud to have secured this deal. We will now enable all of our brands, be it BioGanix or new brands to have exclusive, cutting-edge products – a major differentiator for online D2C retailers swimming in a sea of generics. We would like to thank Dr. Tina Sampalis who sits on the Relevium Board and is also the Chief Science Officer at Tersus for providing this opportunity to us. Dr. Sampalis is credited with the discovery and pioneering of krill oil while she was at Neptune Technologies.”
Mr. Useche went on to say: “The krill oil market is expected to reach USD 709.4 million by 2025. We think that Relevium can be instrumental in building up the Omega 7 market for humans and pets with Provinal® through online marketing in North America. We see a strong opportunity here and are excited to provide access to cutting-edge nutraceuticals to online buyers.”
What is Provinal®?
Provinal® Omega 7 is a novel, patented and clinically-substantiated monounsaturated fatty-acid ingredient targeting the prevention and reversal of dyslipidemia, and cardio-metabolic disorders. Provinal® Omega 7 is a naturally-occurring highly purified monounsaturated fatty acid. Preclinical and clinical evidence has demonstrated a broad range of benefits bridging the treatment gap in highly prevalent disorders with special emphasis on lipid management.
Omega 7 (purified palmitoleic acid) oil of palmitate can potentially help in the fight against diabetes, metabolic syndrome, and atherosclerosis. In this 4-minute video, Dr. Michael F. Roizen, frequent contributor on the Dr. Oz show and Chairman of the Wellness Institute of The Cleveland Clinic, explores the beneficial effects of Provinal® on the management of atherosclerosis, its causes and consequences: heart disease, stroke, memory loss, impotence, and wrinkling.
Purified Omega 7 has been shown to decrease insulin resistance, decrease hepatic fat accumulation, and decrease acute and chronic inflammation – with no known side effects.
Terms of Exclusive Distribution Agreement
Relevium has a two (2) year exclusive distribution agreement for defined online markets in North America, for certain exclusive Relevium formulations formulated with Provinal®. An option for an agreement extension will be evaluated, considered and negotiated by Tersus and Relevium, subject to the fulfillment of the two (2) year Agreement Terms. Any agreement extension would be evaluated, considered and negotiated ninety (90) days prior to its expiration of the second year of the Agreement.
Territory and Channels
The Agreement will grant Relevium exclusive rights to market, sell and distribute the products as described here to the defined online markets in North America for Relevium’s exclusive formulations and brands, with consideration by Tersus for additional countries. Additional or other geographical markets and territories will be agreed upon on a case-by-case basis with final approval to be granted by Tersus, such approval not to be unreasonably withheld. Minimum annual purchases for additional markets and territories will be decided and agreed upon by Tersus and Relevium.
Tersus will provide Relevium with exclusive formulations and product specifications and pricing for custom-formulated Provinal®-based products on an exclusive basis custom designed to target Eye Health and Cardio-metabolic/Metabolic Syndrome. Final formulations, product specifications and product and bottled quantities will be determined and approved by Relevium.
Appointment and Licensee
Tersus will grant Relevium a non-exclusive, personal, limited and non-transferable license for the Term of the Agreement, to use and display the Tersus Provinal® trademarks and Intellectual Property (“IP”) for the sole purpose and in accordance with Relevium’s obligations under the Agreement. Trademarks and IP shall mean those: trademarks, tradenames, service marks, trade dress, logo, copyrights in advertising and promotional materials, website and all website links in the territory, scientific and clinical studies and data.
Scope of Products
Products shall include all Relevium exclusive Provinal® formulated products, the right of first refusal to market, sell and distribute future Tersus Provinal® and Provinal® combination newly-formulated products. Tersus will grant Relevium a right of first refusal to review and evaluate such newly-formulated products after which Relevium will advise Tersus of its acceptance or decline. Acceptance of future Provinal® newly-formulated products will be on an exclusive basis as defined by Relevium’s markets, channels and territories, and as agreed upon in writing.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking information within the meaning of applicable securities legislation, which reflects the Company’s current expectations regarding future events. Forward-looking information is based on several assumptions and is subject to several risks and uncertainties, many of which are beyond the Company’s control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Readers should not place undue reliance on forward-looking statements and forward-looking information and are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake any obligation to update such forward-looking information, whether because of new information, future events or otherwise, except as expressly required by applicable law.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
President and CEO
For more information about this press release:
Tel: +1(514) 562-1374
RELEVIUM TECHNOLOGIES INC